Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
S
SION
vs
S&P 500
S&P 500
Over the past 12 months, SION has underperformed S&P 500, delivering a return of -83% compared to S&P 500's +17% growth.
Stocks Performance
SION vs S&P 500
Performance Gap
SION vs S&P 500
Performance By Year
SION vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Sionna Therapeutics Inc
Glance View
Sionna Therapeutics is a biotechnology company focused on cystic fibrosis, a genetic lung disease. It is developing small-molecule medicines designed to improve the function of the CFTR protein, which is the faulty protein behind cystic fibrosis. In plain terms, Sionna is trying to make better drug combinations that treat the disease at its source rather than only easing symptoms. The company does not sell a broad product line like a traditional drugmaker. Its business is built around research and clinical development, with money coming mainly from raising capital to fund drug development and, if its programs succeed, from future drug sales or licensing deals. Its main end customers would be patients with cystic fibrosis, through doctors, hospitals, and insurers that pay for approved treatments. What makes Sionna different is its focus on a narrow disease area where the biology is well understood and where better CFTR-targeted drugs can still have value. That puts it in the role of a specialized developer inside the drug chain: it discovers and tests medicines, then would hand a successful treatment to the commercial healthcare system or a larger pharmaceutical partner to reach patients.